This week, 7 Biotechnology stocks are improving their overall rating on Portfolio Grader. Each of these rates an “A” (“strong buy”) or “B” overall (“buy”).
Portola Pharmaceuticals, Inc.’s (PTLA) ratings are looking better this week, moving up to a A from last week’s B. The company also gets A’s in earnings revisions. For more information, get Portfolio Grader’s complete analysis of PTLA stock.
Atara Biotherapeutics Inc (ATRA) gets a higher grade this week, advancing from a C last week to a B. The company also gets A’s in earnings revisions. For more information, get Portfolio Grader’s complete analysis of ATRA stock.
Loxo Oncology Inc (LOXO) shows solid improvement this week. The company’s rating rises from a B to a A. For more information, get Portfolio Grader’s complete analysis of LOXO stock.
This week, Vitae Pharmaceuticals, Inc. (VTAE) pushes up from a C to a B rating. The company also gets A’s in earnings surprise. For more information, get Portfolio Grader’s complete analysis of VTAE stock.
Asterias Biotherapeutics Inc Class A (AST) improves from a C to a B rating this week. The company also gets A’s in sales growth. For more information, get Portfolio Grader’s complete analysis of AST stock.
Sophiris Bio Inc. (SPHS) is seeing ratings go up from a B last week to a A this week. The company also gets A’s in earnings revisions. For more information, get Portfolio Grader’s complete analysis of SPHS stock.
Biocept, Inc. (BIOC) boosts its rating from a C to a B this week. Biocept, Inc. is a global provider of clinical trials services, providing medical image management and eClinical services, including electronic data capture and clinical data management solutions. The company also gets A’s in sales growth and earnings momentum. For more information, get Portfolio Grader’s complete analysis of BIOC stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
